RET and neoplasm: Through a large exome study, Agrawal et al. performed tumoural whole exome sequencing on a total of 57 MTCs (36 sporadic) and reported that overall 91% of all tumours had RET (75%), HRAS (12%), or KRAS (4%) mutations [72].